Neural Attunement as a Post-Acute Framework for Stabilizing Neuroplasticity

Summary

Ibogaine leads to significant changes in brain activity during the post-acute period, including reduced neural signal complexity and decreased beta and gamma power, with effects that can last for weeks. This study introduces the Neural Attunement Model, which describes the post-acute phase as a time of organized neuroplasticity characterized by specific electrophysiological markers. The findings suggest that similar effects may occur with other psychedelics, highlighting the importance of understanding this phase.

Study at a glance

Abstract

Dominant psychedelic frameworks have been developed primarily from acute-phase neuroimaging and emphasize transient network reconfiguration during the drug state. Less attention has been given to the post-acute period, during which consequential electrophysiological and clinical changes may unfold. Ibogaine, whose human evidence is restricted to the post-acute window, provides a particularly informative empirical case. Within this window, ibogaine produces a sustained reduction in neural signal complexity, a shift toward low-frequency oscillatory dominance, decreased beta and gamma power, slowed peak alpha frequency, and markers of improved cognitive inhibition that persist for weeks. Comparable longitudinal data from classical psychedelics, including post-acute increases in theta power, lasting prefrontal-subcortical white matter changes, and oscillatory normalization in veteran populations, suggest that the post-acute phase may represent a partially shared regime across compounds. Here, I introduce the Neural Attunement Model as a complementary framework that formalizes the post-acute phase as an organized, low-noise metaplastic window in which stabilizing neuroplasticity unfolds. The framework specifies three convergent features of the post-acute stabilization regime, each operating at a different level of description, identifies electrophysiological markers for the regime, and generates falsifiable predictions that can be tested across compounds and interventions. Post-acute change is already recognized; the contribution here is its specification as a structured, measurable, hypothesis-generating regime with defined electrophysiological criteria. Ibogaine's long half-life, active metabolite noribogaine, and convergent monoamine transporter, glutamatergic, sigma, and neurotrophic actions may extend and stabilize this window beyond durations observed with classical psychedelics, positioning it as the current empirical anchor for a regime that may generalize to other interventions producing comparable post-acute electrophysiological signatures.

Tags